Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction: The PULSE-MI Randomized Clinical...

Area of Science:

• Cardiology
• Pharmacology
• Emergency Medicine

Background:

• Acute inflammation in ST-segment elevation myocardial infarction (STEMI) correlates with myocardial damage extent.
• Early intervention with glucocorticoids may mitigate infarct size.

Purpose of the Study:

• To evaluate the cardioprotective efficacy of prehospital pulse-dose glucocorticoid administration in STEMI patients.

Main Methods:

• A randomized, blinded, placebo-controlled trial involving 530 STEMI patients.
• Patients received either intravenous methylprednisolone (250 mg) or placebo prehospital.
• Primary outcome: final infarct size assessed by cardiac magnetic resonance (CMR) at 3 months.

Main Results:

• No significant difference in final infarct size at 3 months between glucocorticoid and placebo groups (5% vs. 6%, P=.24).
• Glucocorticoid group showed smaller acute infarct size, less microvascular obstruction, and greater acute left ventricular ejection fraction.
• Secondary clinical outcomes and adverse events were similar between groups.

Conclusions:

• Prehospital pulse-dose glucocorticoid did not reduce final infarct size in STEMI patients at 3 months.
• The study may have been underpowered due to smaller-than-anticipated infarct sizes.
• Early administration of glucocorticoids demonstrated potential benefits in acute cardiac parameters.